AXSOME THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

04 Feb 2025 09:19:52 By NetDania Notify

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

31 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

30 Jan 2025 14:45:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

30 Jan 2025 08:45:15 By NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

27 Jan 2025 09:08:34 By NetDania Notify

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

22 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

13 Jan 2025 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

30 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

26 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

13 Nov 2024 08:49:44 By NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

12 Nov 2024 09:02:19 By NetDania Notify

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 06:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

08 Nov 2024 06:00:28 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

29 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

15 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

24 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

04 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in Investor Conferences in September

27 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

21 Aug 2024 06:00:39 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

05 Aug 2024 06:00:00 By Nasdaq GlobeNewswire